Neptune shifts operations
This article was originally published in The Tan Sheet
Executive Summary
Neptune Technologies & Bioresources transfers the license for its cardiovascular application portfolio to operating subsidiary Acasti Pharma to develop active pharmaceutical ingredients for products in the Rx, OTC and medical food markets, the firm announces Aug. 21. Under the arrangement, Quebec-based Acasti will research, develop and market the APIs, with the goal of entering strategic pharmaceutical partnerships. Neptune announced a deal with Yoplait in June 2007 to provide its Neptune Krill Oil - a composition with proprietary omega-3 phospholipids - for use in functional yogurt products (1"The Tan Sheet" July 2, 2007, In Brief)